Oculus Inc. Reports Zero Revenue, Stagnant Financials in Q2 2025

TL;DR

OVTZ is a zombie stock with no revenue or operational activity, avoid it.

AI Summary

OCULUS INC. (OVTZ) reported no revenue for the three and six months ended June 30, 2025, and June 30, 2024, indicating a continued lack of operational income. The company also reported no net income or loss for these periods, maintaining a static financial position. Key business changes were not explicitly detailed in the provided data, suggesting a period of minimal operational activity. The company's financial statements show common stock remaining at 91,422,569 shares for both non-related and related parties as of June 30, 2025, and December 31, 2021. The authorized common stock is 500,000,000 shares with a par value of $0.001 per share. The lack of revenue and net income highlights significant operational challenges and a high-risk strategic outlook for investors. The company's accumulated other comprehensive income and retained earnings also remained unchanged across the reported periods, further emphasizing the stagnant financial performance.

Why It Matters

This filing reveals OCULUS INC. (OVTZ) generated no revenue for the second quarter of 2025, a critical red flag for investors seeking growth or even basic operational activity. The absence of net income or loss, coupled with unchanged equity accounts, suggests the company is either dormant or in a significant transition phase without generating value. For employees, this could signal job insecurity or a lack of future prospects, while customers might question the viability and longevity of any potential products or services. In a competitive market, a company with zero revenue risks being completely overshadowed by active players, making its long-term survival highly questionable.

Risk Assessment

Risk Level: high — The risk level is high because OCULUS INC. reported $0 revenue for both the three and six months ended June 30, 2025, and June 30, 2024. This complete lack of operational income, coupled with no reported net income or loss, indicates severe financial stagnation and an inability to generate business, posing a significant threat to investor capital.

Analyst Insight

Investors should exercise extreme caution and likely avoid OCULUS INC. (OVTZ) given its consistent lack of revenue and operational activity. This filing suggests the company is not actively generating business, making it a speculative investment with substantial downside risk.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

$0

eps

$0.00

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue generated for Q2 2025 or year-to-date 2025, indicating no operational income.)
• $0 — Net Income/Loss (No net income or loss reported for Q2 2025 or year-to-date 2025, reflecting stagnant financial performance.)
• 91,422,569 — Common Shares Outstanding (Number of common shares remained constant from December 31, 2021, to June 30, 2025.)
• 500,000,000 — Authorized Common Shares (Maximum number of shares the company is permitted to issue, significantly higher than outstanding shares.)
• $0.001 — Par Value per Share (Nominal value assigned to each common share.)

Key Players & Entities

• OCULUS INC. (company) — filer of the 10-Q
• OVTZ (company) — ticker symbol for OCULUS INC.
• $0 (dollar_amount) — revenue for Q2 2025 and year-to-date 2025
• 91,422,569 (dollar_amount) — common shares outstanding as of June 30, 2025
• 500,000,000 (dollar_amount) — authorized common shares
• $0.001 (dollar_amount) — par value per common share
• June 30, 2025 (date) — end of the reporting period
• December 31, 2021 (date) — prior balance sheet date for comparison

FAQ

Risk Factors

• Lack of Revenue Generation [high — operational]: OCULUS INC. reported $0 in revenue for the three and six months ended June 30, 2025, and June 30, 2024. This indicates a complete absence of operational income and a significant challenge in generating business activity.
• Stagnant Financial Performance [high — financial]: The company reported $0 net income/loss for the periods ending June 30, 2025, and June 30, 2024. Accumulated other comprehensive income and retained earnings also remained unchanged, highlighting a lack of financial progress.
• High Authorized Share Capital [medium — financial]: With 91,422,569 common shares outstanding and 500,000,000 authorized, the company has substantial room for dilution. This could be a concern for existing shareholders if future capital raises are planned without corresponding operational growth.

Industry Context

OCULUS INC. operates within the business services sector (SIC 7389). This sector is diverse, encompassing a wide range of services. However, the company's current financial state, with no revenue or operational income, suggests it is not actively participating in or benefiting from typical industry activities. The competitive landscape for business services can be intense, requiring innovation and effective service delivery to succeed.

Regulatory Implications

As a publicly traded company, OCULUS INC. is subject to SEC regulations, including timely and accurate financial reporting via forms like the 10-Q. The lack of operational activity and financial results could attract scrutiny from regulators regarding the company's ongoing viability and compliance with listing requirements.

What Investors Should Do

1. Review Previous Filings
2. Seek Clarity on Future Strategy
3. Assess Dilution Risk

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q, showing $0 revenue and $0 net income/loss.
• 2024-06-30: End of Second Quarter 2024 — Comparative period for the 10-Q, also showing $0 revenue and $0 net income/loss.
• 2025-08-08: Filing Date of 10-Q — Indicates the official release of the company's financial performance for the period ending June 30, 2025.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial information for OCULUS INC. for the specified quarter.)

Common Shares Outstanding

The number of shares of common stock that have been issued and are held by investors. (OCULUS INC. has 91,422,569 common shares outstanding, which has remained constant.)

Authorized Common Shares

The maximum number of shares of common stock that a corporation is legally permitted to issue. (OCULUS INC. has 500,000,000 authorized shares, significantly more than outstanding shares.)

Par Value

A nominal value assigned to a share of stock by the company's charter, often a very small amount. (The par value for OCULUS INC.'s common stock is $0.001 per share.)

Accumulated Other Comprehensive Income

A component of shareholders' equity that includes unrealized gains and losses not reported on the income statement. (This account remained unchanged for OCULUS INC., reflecting no new comprehensive income or loss.)

Retained Earnings

The cumulative amount of net income that a company has retained over time, rather than distributing as dividends. (OCULUS INC.'s retained earnings remained unchanged, consistent with its $0 net income.)

Year-Over-Year Comparison

Compared to the prior year's comparable period (ending June 30, 2024), OCULUS INC. shows no change in its financial performance, with both periods reporting $0 revenue and $0 net income/loss. This indicates a continued lack of operational progress and a stagnant financial position. No new risks or significant changes in financial metrics are apparent from the provided data, reinforcing the consistent lack of business activity.

Filing Documents

• ovtz20250630_10q.htm (10-Q) — 678KB
• ex_847098.htm (EX-31.1) — 9KB
• ex_847099.htm (EX-31.2) — 8KB
• ex_847100.htm (EX-32.1) — 5KB
• ex_847101.htm (EX-32.2) — 5KB
• logoxs.jpg (GRAPHIC) — 3KB
• 0001437749-25-025625.txt ( ) — 3179KB
• ovtz-20250630.xsd (EX-101.SCH) — 39KB
• ovtz-20250630_cal.xml (EX-101.CAL) — 21KB
• ovtz-20250630_def.xml (EX-101.DEF) — 208KB
• ovtz-20250630_lab.xml (EX-101.LAB) — 148KB
• ovtz-20250630_pre.xml (EX-101.PRE) — 238KB
• ovtz20250630_10q_htm.xml (XML) — 392KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Forward Looking Statements

Forward Looking Statements 4 Item 1.

Financial Statements

Financial Statements 6 Condensed Interim Consolidated Balance Sheets 6 (A) Condensed Interim Consolidated Statements of Operations and Comprehensive Loss 7 (B) Condensed Interim Consolidated Statements of Stockholders ' Equity (Deficiency) 8 (C) Condensed Interim Consolidated Statements of Cash Flows 10 (D) Notes to Condensed Interim Consolidated Financial Statements 11 Item 2. (E) Management ' s Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 22

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 23 Item 1A.

Risk Factors

Risk Factors 23 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23 Item 3. Defaults Upon Senior Securities 23 Item 4. Mine Safety Disclosure 23 Item 5. Other Information 23 Item 6. Exhibits 23 3 Table of Contents

FORWARD LOOKING STATEMENTS

FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical fact are "forward-looking statements" for the purposes of this Quarterly Report on Form 10-Q. In some cases, you can identify these statements by forward-looking words such as "plan", "may", "will", "expect", "intend", "anticipate", believe", "estimate" and "continue" or similar words. Forward-looking statements are statements that are not historical facts, and include, but are not limited to: o our digital watermarking technology and Cloud-based document protection system; o our data privacy and data protection services and solutions; our technology, our cash needs, including our ability to fund our future capital expenditures and working capital requirements; o our expectations regarding competition and growth in our sector; the future sources and availability of additional funding; and o the effect of funding arrangements on projects and products. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control. Accordingly, we do not undertake any obligation to update any forward-looking statements for any reason, even if new information becomes available or other events occur in the future, except as required by law. Forward-looking statements are based on current expectations about future events affecting the Company and are subject to uncertainties and factors that affect all business operating in a global market as well as matters specific to the Company. These uncertainties and factors are diff

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. OCULUS INC. AND SUBSIDIARY CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Stated in US Dollars) (Unaudited) June 30, 2025 December 31, 2024 ASSETS Current Assets: Cash $ 8,196 $ 11,718 Prepaid expenses and other current assets (Note 4) 15,600 27,822 Total Assets $ 23,796 $ 39,540 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY) Current Liabilities: Accounts payable and accrued liabilities (Note 5) $ 120,471 $ 105,651 Accounts payable and accrued liabilities - related parties 475,625 343,362 Total current liabilities 596,096 449,013 Stockholders' Equity (Deficiency): Preferred stock - no par value; authorized 250,000,000 shares, none issued Common stock and additional paid-in capital - no par value; authorized 500,000,000 shares, issued and outstanding 91,422,569 and 91,422,569 as at June 30, 2025 and December 31, 2024 respectively 46,850,710 46,850,710 Additional paid in capital 1,485,000 1,485,000 Accumulated other comprehensive loss ( 39,376 ) ( 31,177 ) Accumulated deficit ( 48,868,634 ) ( 48,714,006 ) Stockholders' equity (deficiency) ( 572,300 ) ( 409,473 ) Total Liabilities and Stockholders' Equity (Deficiency) $ 23,796 $ 39,540 Going concern (Note 2) SEE ACCOMPANYING NOTES 6 Table of Contents OCULUS INC. AND SUBSIDIARY CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Stated in US Dollars) (Unaudited) For the three months ended June 30, For the six months ended June 30, 2025 2024 2025 2024 Expenses: Consulting (Note 11) $ 15,000 $ 30,750 $ 30,000 $ 61,250 Research and development (Note 10) 183 2,551 460 4,731 Selling, general and administrative (Notes 9 and 11) 36,615 46,055 124,252 93,239 Stock-based compensation (Notes 7 and 11) - 1,287 - 5,679 Loss from operations ( 51,798 ) ( 80,643 ) ( 154,712 ) ( 164,899 ) Interest income 80 672 84 2,112 Net loss ( 51,718 ) ( 79,971 ) ( 154,628 )

View Full Filing

View this 10-Q filing on SEC EDGAR